Controversies in borderline ovarian tumors.
10.3802/jgo.2015.26.4.343
- Author:
Seok Ju SEONG
1
;
Da Hee KIM
;
Mi Kyoung KIM
;
Taejong SONG
Author Information
1. Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea. hoyasama@chamc.co.kr
- Publication Type:Review
- Keywords:
Borderline Ovarian Tumors;
Data Collection;
Fertility;
Management
- MeSH:
Biopsy;
Chemotherapy, Adjuvant;
Female;
Humans;
Infertility, Female/prevention & control;
Intraoperative Care/methods;
Laparoscopy/methods;
Laparotomy/methods;
Neoplasm Recurrence, Local/therapy;
Neoplasm Staging;
Organ Sparing Treatments/methods;
Ovarian Neoplasms/pathology/*therapy;
Ovary/*pathology;
Precancerous Conditions/pathology/therapy
- From:Journal of Gynecologic Oncology
2015;26(4):343-349
- CountryRepublic of Korea
- Language:English
-
Abstract:
Borderline ovarian tumors (BOTs) represent about 15% to 20% of all ovarian malignancies and differ from invasive ovarian cancers (IOCs) by many characters. Historically, standard management of BOT is peritoneal washing cytology, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, complete peritoneal resection of macroscopic lesions; in case of mucinous BOTs, appendectomy should be performed. Because BOTs are often diagnosed at earlier stage, in younger age women and have better prognosis, higher survival rate than IOCs, fertility-sparing surgery is one of the option to preserve childbearing capacity. The study of such conservative surgery is being released, and still controversial. After surgery, pregnancy and ovarian induction followed by in vitro fertilization are also significant issues. In surgery, laparoscopic technique can be used by a gynecologic oncology surgeon. So far postoperative chemotherapy, radiotherapy and hormone therapy are not recommended. We will discuss controversial issues of BOTs on this review and present the outline of the management of BOTs.
